Olodanrigan sodium
Based on 4 publication(s) in Google Scholar
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1316755-17-5
- Fòrmula: C32H28NNaO5
- Peso molecular:529.56
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Olodanrigan sodium
MoreVer todos los productos específicos de isoformas Angiotensin Receptor
More
Actividad biológica
|
AT2 Receptor |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1316755-17-5
-
Peso molecular 529.56
-
Fòrmula C32H28NNaO5
-
SMILES
O=C([C@H]1N(C(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)CC4=C(C(OCC5=CC=CC=C5)=C(OC)C=C4)C1)O[Na]
-
Synonyms
EMA401 sodium; PD-126055 sodium
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Environ Int
PPARγ-SMAD6 axis-mediated inhibition of osteogenic differentiation is involved in BPS-induced osteoporosis. [Abstract]2025 Apr 6:198:109442. PMID: 40215917 -
Radiother Oncol
Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1α-HILPDA axis. [Abstract]2024 Dec 19:110686. PMID: 39709027 -
J Pharmacol Sci
EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome. [Abstract]2021 Jul;146(3):121-124. PMID: 34030794 -
Neurosci Lett
A novel angiotensin II type 2 receptor antagonist TDI05 alleviates the peripheral neuropathic pain. [Abstract]2025 Aug 28:138369. PMID: 40885515
Pureza y Documentación
Referencias
[1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637-47. [Content Brief]
[2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Olodanrigan sodium Related Classifications
HY-13106A Related Classifications
Powered by Bioz